| OBSERVATION'S | ImClone's president and CEO, Samuel D. Waksal, has admitted to serious mistakes in handling clinical trial data, making any near-term approval unlikely |
| UPDATE | 02.02 |
| CONTACT | This data is not available for free |
| LITERATURE REF. | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |